CClinicalTrials.gg
CompletedNCT03371615LeopardUpdated Dec 30, 2021

Evaluation of the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula

An interventional study of Anti-regurgitation infant formula in Regurgitation, Gastric, sponsored by Nutricia Research. Completed at 2 sites in Poland. Open to participants aged 3 Weeks to 13 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-30.

Sponsored by Nutricia Research · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
3 Weeks to 13 Weeks
Sex
All
01

Study summary

A randomised, controlled, double-blind trial to evaluate the tolerance and safety of a new partly fermented anti-regurgitation infant formula containing prebiotics and locust bean gum in infants with regurgitation.

02

Conditions studied

  • Regurgitation, Gastric
03

Who can participate

Ages eligible
3 Weeks to 13 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Singleton healthy term infant aged 3 - 13 weeks;
  2. Gestational age at birth 37- 42 weeks;
  3. Normal birth weight for gestational age and gender i.e. 10th to 90th percentile compared to the WHO or local growth charts;
  4. Infants with regurgitation that are otherwise healthy, based upon the following criteria: 1) Regurgitation of 2 or more times per day for 1 or more weeks according to reported history, 2) an indication for the use of AR formula according to the investigator at screening/randomisation.
  5. Fully formula fed for at least 7 days before screening/randomisation;
  6. Written informed consent from the parent(s) and/or legally acceptable representative(s), aged ≥ 18 years.

Exclusion criteria

-

Exclusion Criteria:

    1. History of retching, hematemesis, aspiration, apnoea, failure to thrive, feeding or swallowing difficulties or abnormal posturing; 2. Gastrointestinal infection within 4 weeks prior to randomisation; 3. Congenital condition and/or previous or current illness and (or) medication use that could interfere with the main study outcomes according to the investigator; 4. Known cow's milk protein allergy, lactose intolerance, or galactosaemia including history of any other allergic manifestations or known allergy to any of the study product ingredients (especially scGOS); 5. Presence of any other gastrointestinal symptom(s)/disorder(s) that are not functional in nature, as assessed by the investigator's clinical judgement; 6. Received any of the following products/medication prior to randomisation: systemic antibiotics, prokinetics, proton pump inhibitors, complementary feeding/weaning within 4 weeks prior to randomisation; 7. Incapability of the parent(s) to comply with the study protocol or investigator's uncertainty about the willingness or ability of the parent(s) to comply with the protocol requirements; 8. Current participation in another clinical intervention study.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
182 participants (actual)

Study arms

  • Active comparator
    Fermented IF + LBG + Gos Fos

    Fermented infant formula with Locust bean gum and Gos Fos

    Other: Anti-regurgitation infant formula

  • Placebo comparator
    Fermented IF +LBG

    Fermented infant formula with Locust bean gum

    Other: Anti-regurgitation infant formula

Interventions

  • OtherAnti-regurgitation infant formula

    Anti regurgitation infant formula

05

What researchers measure

Primary outcomes

  1. GI tolerance

    To assess the gastrointestinal (GI) tolerance of the investigational product compared to the control product based on Infant Gastrointestinal Symptom Questionnaire(IGSQ) symptoms score containg 13 questions on a 7 point scale

    Time frame: 4 weeks

06

Study locations

2 sites
  • Poliklinika Ginekologiczno-Poloznicza Sp. Z.O.O Sp.K
    Białystok, 15-435, Poland
  • Centrum Medyczne Promed
    Kraków, 31411, Poland
07

References and documents

Publications

  • Bellaiche M, Ludwig T, Arciszewska M, Bongers A, Gomes C, Swiat A, Dakhlia F, Piollet A, Oozeer R, Vandenplas Y. Safety and Tolerance of a Novel Anti-Regurgitation Formula: A Double-Blind, Randomized, Controlled Trial. J Pediatr Gastroenterol Nutr. 2021 Nov 1;73(5):579-585. doi: 10.1097/MPG.0000000000003289. PubMed 34417399 ↗
08

Registry details

Key details

Study ID
NCT03371615
Lead sponsor
Nutricia Research
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Nov 4, 2017
Primary completion
Sep 6, 2019
Completion
Sep 6, 2019
Last update
Dec 30, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion